Kornimate/medical-research-clean huggingface dataset:
assessing the relationship between chronic pain and frailty in older adults

Conditions: Chronic Pain; Frailty

Summary: pain is an unpleasant emotional sensation related to one's past experiences, originating from a certain part of the body, due to tissue damage or not. pain is the most commonly reported symptom in the elderly. chronic pain is persistent or recurrent pain lasting more than 3 months. it is a maladaptive process or a disease that requires multimodal treatment that causes functional decline, independent of the healing process, accompanied by affective, cognitive and motivational disorders, and deterioration in quality of life. frailty: it is defined as a clinical condition characterized by weakness, physical disability, functional regression, inadequacy in activities of daily living, and increased dependence, which develops as a result of the decrease in physiological reserves in the body with age. it has been reported that the risk of falls, disability, hospitalization and premature death is higher in the frail elderly. the prevalence of vulnerability in societies varies. frailty rates ranging from 4 to 59% have been reported in developed and developing countries. in this study, it was aimed to evaluate whether there is a relationship between chronic pain and frailty in individuals aged 65 and over.


Eligibility criteria:
inclusion criteria: * patients with chronic pain who are registered with a family medicine unit exclusion criteria: * having an active malignancy, * having a physical disability, * being bedridden, * having a psychotic disorder, * having a cognitive disorder, and refusing to participate.
boiled peanut oral immunotherapy

Conditions: Peanut Hypersensitivity

Summary: prospective phase 1 clinical trial providing proof of concept data on boiled peanut oral immunotherapy (oit) for the treatment of peanut allergy in children. the investigators hypothesize that the proportion of subjects successfully desensitized with boiled peanut oit is greater than the theoretical placebo rate of 20%.

oral immunotherapy will be administered utilizing a powder derived from boiled peanuts. treatment will begin with an initial escalation day in which dosing is begun at 0.1 mg peanut protein and escalated to a final dose of 6 mg peanut protein. doses are ingested orally. participants will continue daily oral ingestion of doses at home and return for updosing every 2 weeks to a final maintenance dose of 300 mg peanut protein. participants will continue daily oral ingestion of the peanut product for a minimum duration of 28 days before undergoing exit double blind placebo controlled food challenge. at the conclusion of the study, participants will be offered continued maintenance therapy off study in line with current specialty standards.

Eligibility criteria:
inclusion criteria: * age 1-16 years * history of immediate hypersensitivity reaction to peanut * evidence of ige mediated peanut hypersensitivity within a 12 month period of study enrollment * spt with wheal/flare of at least 3 x 6 mm and/or peanut specific ige \>0.35 ku/l exclusion criteria: * history of life threatening peanut anaphylaxis * asthma requiring more than medium dose ics * prior participation in oral immunotherapy, sublingual immunotherapy or epicutaneous immunotherapy * oat allergy * cardiovascular disease * use of beta-blockers (oral), angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or calcium channel blockers * use of steroid medications in the following manners: * daily oral steroid dosing for greater than 1 month during the past year * burst or steroid course in the past 3 month before inclusion * greater than 2 bursts oral steroid courses in the past year of at least 1 week duration * pregnancy or lactation * eosinophilic gastrointestinal disease * history of food protein-induced enterocolitis * history of developmental delay or speech delay that precludes age- appropriate communication, in the opinion of the investigator

Keywords: peanut allergy
a registry of al amyloidosis (real)

Conditions: AL Amyloidosis

Summary: the purpose of this protocol is to generate a large registry of patients with al amyloidosis.

thanks to this registry, it will be possible to collect data at diagnosis and during follow up, in order to be able to describe the natural history of al amyloidosis in a real-world setting and to define and validate prognostic models, response and relapse criteria applicable at any point of the disease.

Eligibility criteria:
inclusion criteria: 1. diagnosis of systemic al amyloidosis; 2. treatment-naïve (pre-treatment data collected at participating center available for retrospective part); 3. age ≥18 years; 4. ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted); 5. planned (or ongoing) follow-up at participating center. exclusion criteria: 1. non-al amyloidosis; 2. previous treatment for al amyloidosis.

Keywords: amyloidosis prognosis registry
effects of the smartdrive on mobility, activity and shoulder pain among people with sci using manual wheelchairs

Conditions: Spinal Cord Injuries

Summary: this is a prospective study of manual wheelchair users with spinal cord injury (sci). the users will be their own controls. the primary purpose of the study is to evaluate the ability of the power assist device smartdrive to increase the ability to be mobile.

the hypothesis of the study is that the smartdrive will enable the user to be more active, both in commuting longer distances with less strokes needed, and managing single difficulties stopping them from activity. the two assessments selected, distance travelled and the daily diary, should directly reflect the impact of the smartdrive. in addition, the the international spinal cord society (iscos) pain data set, wheelchair user's shoulder pain index (wuspi) and wheelchair outcome measure (whom) will be used. in whom, the participants will state some activities they perform in their wheelchair that are important to them, and how satisfied they are with their current level of performance of that activity. after the intervention period the satisfaction is reassessed. this will enable to capture the effect smartdrive usage has on the participant's daily life (beyond distance commuted and pain level). after enrollment, the participants will be followed for two weeks using their wheelchair without smartdrive. after attaching the smartdrive, they will have three weeks to get into a use of the device on a regular basis in their everyday life, and then follows two consecutive weeks of study intervention and data collection. to capture the long-term effect and allow for season variability, follow-up data will be collected at three and six months after start of study intervention.

Eligibility criteria:
inclusion criteria: * capable of giving signed informed consent which includes compliance with the requirements listed in the informed consent form (icf) and in this protocol * 18 years of age inclusive, at the time of signing the informed consent. * motor level c6-l3 spinal cord injury, american spinal injury association impairment scale (ais) a-c since at least six months * full time manual wheelchair users, able to propel their own wheelchairs independently * eligible reason for smartdrive prescription (self-reported shoulder pain, and/or decreased physical endurance for propulsion, limiting user from activity) exclusion criteria: * cognitive impairment affecting the ability to operate the smartdrive, as deemed by prescribing clinician * weigh more than 150 kilos due to the technical specification of the smartdrive * currently participating in another clinical study anticipated to affect the outcome or ability to compete this study * planned change from daily routines during the following two months, such as holiday, move, change jobs * for any other reason not suitable for participation in the study, as deemed by prescribing clinician * do not use a smart phone
differentially expressed proteins in sporadic parathyroid tumors

Conditions: Primary Hyperparathyroidism; Hypercalcemia

Summary: primary hyperparathyroidism (phpt) is one of the common endocrine disorders. the major clinical symptoms involve stones, bones, abdominal groans and psychiatric moans. increased parathyroid cell proliferation and decreased calcium-mediated control of the pth secretion are characteristic findings. the most common cause of phpt is adenoma followed by hyperplasia and carcinoma.the molecular mechanisms involved in parathyroid tumorigenesis are partially known. few genes have been identified and their roles are under study. the genes which are under study by different groups are unable to give a definite direction towards the understanding of parathyroid tumorigenesis and the mechanism involved in overgrowth of parathyroid tissue. so identifying different proteins and their regulation pattern from adenomas to carcinomas will be the initial steps towards understanding the proteins involved in tumorigenesis of parathyroid tissues. by using proteomics approach one can generate protein level information. in this study, using a combined approach based on 2 d gel electrophoresis and mass spectrometry (ms), the investigators propose to study a comparative proteomics to examine the changes of protein profiles in parathyroid tumor tissues with normal and hyperplasic parathyroid tissues. this work plan will help us to understand differentially expressed proteins in patients with phpt. this will help in understanding the disease and identifying better diagnostic and curative measures of the disease. the investigators are also planning to access nuclear morphometry changes in sporadic parathyroid tumors. it will help in establishing cellular and nuclear change pattern variations from normal to parathyroid tumors.

subjects: all the phpt patients attending outdoor patient clinic of endocrinology and general surgery department of nehru hospital, pgimer, chandigarh will be enrolled in this study. sample collection: a parathyroid tissue sample will be taken from the patients undergoing for parathyroidectomy. samples will be collected immediately after surgery, snap frozen and stored at -80oc until use. in addition 10 ml of blood will also be taken from these patients for estimating biochemical parameters. controls: normal parathyroid gland will be used as control and it will be obtained from patient undergoing thyroidectomy for multinodular goiter as an elective procedure at the institute.

Eligibility criteria:
inclusion criteria: * phpt patients with parathyroid adenoma, hyperplasia and carcinoma exclusion criteria: * patients with family history, hpt-jt syndrome and familial isolated hyperparathyroidism

Keywords: parathyroid gland primary hyperparathyroidism proteins
endoscopic interventions in patients with covid-19

Conditions: Change; Endoscopy, COVID-19

Summary: this is a combined study including a descriptive part about the preparations for covid-19 and the impact of covid-19 on the daily routine of the work in an interdisciplinary endoscopic unit (ieu), and a point-prevalence analysis for possible positive sars-cov-2 carriers among the staff of the ieu, and finally a prospective analysis of sars-cov-2 positive patients who required endoscopic intervention. results are presented in the captures: 1. sars-cov-2-pandemic related restructuring of the processes in the ieu, 2. sars-cov-2-pandemic related impact on the staff of the ieu, and 3. analysis of endoscopic interventions in patients with confirmed or suspected sars-cov-2 infection.

this article is intended to provide an overview of the impact of the covid-19 pandemic on an interdisciplinary endoscopy unit (ieu, gastroenterological endoscopy, surgical endoscopy, and bronchoscopy) at the university hospital tübingen, a center for tertiary care in south-western germany. first, preparations for covid-19 pandemic with respect to the ieu are presented, and compared with those of other endoscopy units (7, 8). additionally, the direct impact of sars-cov-2 on the staff of the ieu will be shown, together with a point-prevalence analysis of sars-cov-2 of the staff at the end of the sars-cov-2 wave in tübingen. finally, to our knowledge for the first time, we conducted a prospective single center analysis of the patients infected with sars-cov-2, which required a diagnostic or therapeutic endoscopic intervention.

Eligibility criteria:
inclusion criteria: * patients with proven or suspected infections with sars-cov-2 infection, who required endoscopic interventions exclusion criteria: * all other patients
a study to isolate and test circulating tumor cells using the clearcell® fx ep+ system

Conditions: Lung Cancer; Lung Neoplasms; Cancer of Lung; Cancer of the Lung; Neoplasms, Lung; Neoplasms, Pulmonary; Pulmonary Cancer; Pulmonary Neoplasms; Carcinoma, Non-small-cell Lung; Adenocarcinoma; Squamous Cell Carcinoma

Summary: the purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. in this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.

the plan is to collect both blood and tumor samples from the patient's lung cancer in order to validate this technology in detecting circulating tumor cells. the investigators will also obtain a postoperative blood sample to see if there is a decrease in the overall circulating tumor cell measurement once the tumor has been surgically removed.

Eligibility criteria:
inclusion criteria: * stage ib and above non-small cell lung cancer or metastatic lung cancer * age \>18 years old * willing and able to consent to study * no prior history of neoadjuvant therapy. exclusion criteria: * age \<18 years old * unable to provide consent
the neural correlates of food choice decision-making in obesity and weight loss

Conditions: Obesity; Weight Loss; Weight Control

Summary: this study is designed to determine whether obese, normal weight, and successful weight loss maintainers differ in their food choice decision-making and/or executive function, and whether participation in a behavioral weight loss program leads to neural and/or behavioral changes. the investigators will examine behavioral performance on several tasks involving decision-making and self-control in conjunction with brain imaging data acquired during a food-choice decision-making task. participants enrolled in the behavioral weight loss program will also be assessed following the treatment.


Eligibility criteria:
inclusion criteria: * women, ages 35-55, who are either currently obese (bmi = 30-40 kg/m2), always normal weight (lifetime bmi \< 25, nw) or successful weight loss maintainers who have lost 10% of their body weight and maintained that loss for at least 1 year (lifetime maximum bmi = 30-40 kg/m2) exclusion criteria: * weight loss medications, binge eating, standard mri contraindications (e.g., metal implants, claustrophobia, pregnancy), left-handedness, food allergies, neurological or psychiatric conditions, including but not limited to schizophrenia, bipolar disorder, epilepsy, stroke and traumatic brain injury with loss of consciousness, and, among obese participants, inability to participate at two time points and lack of interest in participating in a behavioral weight loss trial * serious current physical disease (e.g., heart disease and cancer) for which physician supervision of diet and exercise prescription is needed, physical problems that limit the ability to exercise, participation in a weight loss program in the last 2 months and intention to become pregnant in the next 6 months
expressive arts as a social and community integration tool for youth recovering from brain injury

Conditions: Brain Injuries

Summary: this study utilizes a novel technique-expressive arts therapy-to facilitate social integration for youth recovering from acquired brain injury (abi). expressive arts therapy is defined as the use of the arts and artistic media to explore psychological aspects of life. an expressive art (also referred to as 'creative arts' or even just 'arts') encompasses drama, music, art (visual arts such as painting, sculpture etc) and dance/movement. it has great potential to improve community integration for youth recovering from abi, through facilitating skills required for successful social communication and social cognition. it is hypothesized to improve social and emotional functioning compared to a less structured creative arts program. it is expected that a combination of directed group activities and self-reflection within a creative learning context will improve emotional awareness and social and community integration to a greater degree than a non-expressive creative arts therapy group, in youth who have suffered an abias community integration enables meaningful and productive occupational engagement, enabling opportunities for occupational engagement through increased community integration would greatly enhance the quality of life of adolescents with abi.


Eligibility criteria:
inclusion criteria: * at least 6 months post injury * difficulties in social and emotional functioning * entering grades 10 and 11 in 2007 * english fluency exclusion criteria: * extreme behaviour, mood and cognitive disturbance
platelet-rich plasma (prp) injection for treating shoulder subacromial impingement syndrome

Conditions: Shoulder Impingement Syndrome

Summary: the purpose of this study is to determine whether injection of platelet-rich plasma derived from patient's blood is effective in treatment of shoulder subacromial impingement syndrome as compared to the current protocol of methylprednisolone injection.

patients presenting with shoulder pain to the study location will be screened by the principal investigator. once diagnosed clinically with shoulder subacromial impingement syndrome, they will be invited to join the study. they will be invited to separate academic office to be explained about the study, its voluntary and confidential basis as per our institutional review board (irb) approved protocols. after signing informed consent form and recruitment, they will be assigned randomly to one of the study arms through software-generated sequential allocation packaged in an opaque envelope. all involved except the principal investigator and patient are blinded. there are two groups/arms in the study. the experimental arm will include subacromial injection of study subjects with autologous platelet-rich plasma; wheres subjects in the other study arm will be injected with methylprednisolone. the outcome will be assessed through three scores. the study subjects will be asked to complete oxford shoulder score questionnaire and health-related quality of life sf-36 questionnaire and constant-murley score will be measured through physician-based assessment done by the residents involved in the study. this will be done during the baseline visit before injection and repeated at 2, 6, 12 weeks and 6 months follow-up visits. also any adverse effects of both treatment arms will be monitored and reported as appropriate. the investigators hypothesize that injecting platelet-rich plasma into the subacromial space of patients with subacromial impingement will result in decreased pain and increased function at 6 months follow-up (assessed by constant-murley score, oxford shoulder score, and short form-36 (sf-36) questionnaire) as compared to patients injected with methylprednisolone.

Eligibility criteria:
inclusion criteria: * any adult male or female between 18 and 65 years of age, inclusive, with clinical diagnosis of shoulder subacromial impingement exclusion criteria: * age below 18 or above 65 years * history of prior shoulder injections or surgery * history of fracture of the acromion, clavicle, scapula, or proximal humerus * known allergy to corticosteroids * known allergy to lidocaine

Keywords: subacromial injection methylprednisolone treatment platelet-rich plasma
dreams and bereavement

Conditions: Healthy Subjects

Summary: the aim of the study is to investigate a possible role of dreaming in emotion regulation testing whether dreaming of a close relative recently deceased is correlated with a positive evolution of the bereavement process


Eligibility criteria:
inclusion criteria: * age \> or = 18 years old * the death of a close relative in the last 3 months exclusion criteria: - history of psychiatric and neurologic disease

Keywords: dreams bereavement emotional regulation bereavement
physiotherapy in patients in a cardiac intensive care unit

Conditions: Cardiac Surgery Patients

Summary: background. cardiovascular diseases are a major cause of morbidity and mortality. the management of these patients requires multidisciplinary therapeutic approaches. physiotherapy plays a fundamental role in the postoperative management of patients undergoing cardiac surgery. objective: to analyse the relationship between the administration of a physiotherapy intervention and the time spent in the cardiac icu and on the ward. method. retrospective cohort study. the medical records of 110 patients undergoing cardiac surgery who received a physiotherapy intervention during their stay in the intensive care unit will be analysed. data will be collected from patients admitted to the cardiac icu in 2023. the variables assessed will be: length of stay in icu and hospital admission (days), age (years completed), weight (kg) and sex. a one-factor analysis of variance will be performed to calculate the association between the variables and a linear regression analysis will be used to describe the hospital stay variables as a function of the other predictor variables. expected outcomes. physiotherapy treatment in an intensive care unit improves icu and hospital stay times in patients undergoing cardiac surgery.


Eligibility criteria:
inclusion criteria: * patients diagnosed with cardiac pathology * undergoing cardiac surgery at the hospital universitario central de asturias between 1 january and 31 march 2023 * in the postoperative phase in the intensive care unit and subsequently on transfer to the ward, they received physiotherapy treatment or not. * that the period of stay in the icu was less than 30 days. exclusion criteria: * patients with comorbidities prior to surgery that hindered independence from third parties in the performance of activities of daily living and ambulation; iii) patients with previous cardiac surgeries; and iv) patients whose study variables were not fully recorded in the medical history. * patients with previous cardiac surgeries * patients whose study variables were not fully recorded in the clinical history.

Keywords: physiotherapy intensive care unit postoperative complications prevention cardiac surgery